Vivoryon Therapeutics N.V. (VIE:VVYN)

Market Cap	36.43M -4.2%
Revenue (ttm)	n/a
Net Income	-6.77M
EPS	-0.23
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	1.180
Previous Close	1.180
Day's Range	1.180 - 1.230
52-Week Range	1.025 - 1.780
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 6, 2026

About Vivoryon Therapeutics

Vivoryon Therapeutics N.V. operates as a clinical stage biopharmaceutical company that focuses on research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company’s lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer’s disease. In addition, the company is developing a monoclonal antibody PBD-C06 is for N3pE-Abeta. Vivoryon ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1997
• Employees: 13
• Stock Exchange: Vienna Stock Exchange
• Ticker Symbol: VVYN

Financial Performance

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Aug 7, 2026

Data Sources Report a data error